Form 4: Oruka Therapeutics Grants Long-Term Stock Options to Key Directors and 10% Owners

Oruka Therapeutics, Inc. has granted 17,500 stock options to entities and individuals associated with Fairmount Funds Management LLC, including directors Peter Harwin and Tomas Kiselak, aligning their interests with the company's long-term performance.

Summary

• Oruka Therapeutics, Inc. (ORKA) granted 17,500 stock options to Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Peter Evan Harwin, and Tomas Kiselak.
• The stock options have an exercise price of $11.77 per share.
• The options begin vesting monthly from June 2, 2025, subject to the recipient's continued service to the Issuer.
• The expiration date for these stock options is June 1, 2035.
• Peter Harwin holds the option for the benefit of Fairmount investment vehicles and disclaims beneficial ownership of the option and underlying common stock.
• Fairmount disclaims beneficial ownership of any reported securities, except to the extent of its pecuniary interest therein.
• Fairmount entities are deemed directors by deputization due to Peter Harwin's service on the board of directors of Oruka Therapeutics and his role as a manager of Fairmount.

Sentiment

Score: 7

Explanation: The grant of stock options to directors and significant shareholders is generally a positive signal, indicating alignment of interests and long-term commitment. The specific terms (exercise price, vesting schedule) are standard for such incentives, contributing to a moderately positive sentiment.

Positives

• The grant of 17,500 stock options to directors and significant shareholders (10% owners) aligns their financial interests directly with the long-term success and shareholder value creation of Oruka Therapeutics.
• The long vesting period, commencing monthly from June 2, 2025, and the distant expiration date of June 1, 2035, indicate a sustained, long-term commitment from these key stakeholders to the company's performance.

Risks

• The value of the granted stock options is inherently dependent on the future market performance of Oruka Therapeutics' common stock, introducing market risk.
• The vesting of the options is contingent upon the recipient's continued service to the Issuer, meaning unvested options could be forfeited if service ceases.

Future Outlook

The granting of long-term stock options to key directors and significant shareholders suggests an expectation of future growth and value creation for Oruka Therapeutics, incentivizing these stakeholders over the next decade to contribute to the company's success.

Management Comments

• "This option represents a right to purchase 17,500 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2025, subject to the recipient's continued service to the Issuer."
• "Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a 'Fairmount Fund'). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund."
• "Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock."
• "Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."
• "Fairmount, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest III L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount."

Industry Context

This Form 4 filing reports a standard insider transaction involving the grant of stock options, a common practice in the biotechnology or pharmaceutical industry (indicated by 'Therapeutics' in the company name) to incentivize directors and significant investors. Such equity grants are typical for aligning long-term interests in companies that often have extended development cycles and require sustained commitment from key personnel.

Corporate Governance

Related Party Transactions

• The stock option grant to Peter Harwin, who is a managing member of Fairmount Funds Management LLC, and the subsequent arrangement where he holds the option for the benefit of Fairmount investment vehicles, constitutes a related party transaction. This structure ensures that the economic benefit of the option accrues to the Fairmount Funds, aligning the interests of these investment vehicles with the company's performance.

Stakeholder Impact

• **Shareholders**: The grant of options to key directors and 10% owners aligns their interests with long-term shareholder value creation, potentially leading to improved company performance. However, it also introduces potential future dilution if the options are exercised.
• **Management/Directors**: Provides a significant long-term equity incentive for Peter Harwin and Tomas Kiselak, and indirectly for the Fairmount entities, motivating them to contribute to the company's sustained success.

Next Steps

• The 17,500 stock options will continue to vest monthly from June 2, 2025, over a 12-month period.
• The reporting persons may exercise the vested options before their expiration date of June 1, 2035.

Key Dates

Recommendation

Keywords

Oruka Therapeutics, ORKA, SEC Form 4, Stock Option Grant, Insider Transaction, Beneficial Ownership, Fairmount Funds Management, Peter Harwin, Tomas Kiselak, Director Compensation, Equity Incentive, 10% Owner